Global HER2 Positive Breast Cancer Market Overview
HER2-Positive Breast Cancer Market accounted for US$8.0 billion in 2020 and is estimated to be US$12.3 billion by 2030 and is anticipated to register a CAGR of 4.3%.
HER2-positive breast cancer treatment refers to a type of breast cancer in which a test revealed the presence of the protein human epidermal growth factor receptor 2 (HER2), which influences cancer cell proliferation. Anyone who has been diagnosed with breast cancer should be examined for the presence of HER2. HER2-positive tumours (also known as HER2-positive tumours) were previously linked to an increased risk of recurrence and mortality from breast cancer. The prognosis of HER2-positive breast tumours has significantly improved with the use of chemotherapy and targeted treatment against HER2. The term "neoadjuvant therapy" refers to treatment provided prior to surgery with the intention of shrinking the tumour before it is removed. The term "adjuvant therapy" refers to treatment provided after surgery with the purpose of eradicating any cancer cells that may have survived (and potentially spread).
Impact of Covid-19 pandemic on market
The virus originally surfaced in late 2019 and has since expanded globally. To slow the spread of the virus, residents in several places have been advised to stay at home as much as possible. This is especially relevant for cancer patients, as many of them are at an elevated risk of serious sickness if they are exposed to COVID-19. This risk must be weighed against the importance of continuing to receive regular medical care in order to monitor and treat their cancer. Increased government assistance, favourable government programmes, research institutes, clinics, and healthcare systems, as well as a variety of other groups, can all aid in the fight against the COVID-19 pandemic.
Global HER2 Positive Breast Cancer Market Dynamics
Growth in business operations by emerging and small sized players
The expansion of this industry is due to emerging markets and significant investment in research & development. The rise in cases of HER2-positive breast cancer around the world has influenced the demand for novel medications for HER2-positive breast cancer therapy, which has fueled the expansion of the HER2-positive breast cancer treatment market. Furthermore, high immunotherapy acceptance and favourable reimbursement are seen as encouraging signs for the treatment of HER2-positive breast cancer. The market for HER2-positive breast cancer treatment is thought to be limited by high treatment costs and the cancellation of late-stage clinical trials.
Global HER2 Positive Breast Cancer Market Segmentation
HER2-Positive Breast Cancer market is segmented based on Treatment type, Route of Administration, Application, Distribution channel and Region.
On the basis of Treatment type, the HER2-Positive Breast Cancer market is segmented into Targeted therapy, Chemotherapy, Endocrine therapy, Immunotherapy and Others. Based on Route of Administration, the target market is segmented into Parenteral, Oral and Others. On the basis of Application, the target market is segmented into Hospitals, Biotechnology & Pharmaceutical company, Specialty Clinics, Research & Academic Institution and Others. By Distribution channel, the target market is segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy.
Regional Insights:
On region the HER2-Positive Breast Cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America will hold the largest market share for HER2-positive breast cancer therapy in the upcoming forecast era, followed by Europe, because of the growth in incidences of HER2-positive breast cancer and favourable government regulations as well as advanced healthcare facilities. Due to increased government initiatives and quickly expanding disposable income, Asia-Pacific has emerged as the fastest growing geographic category in terms of sales.
HER2-Positive Breast Cancer Market Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2030 |
|
Market Segmentation |
By Treatment type- Targeted therapy, Chemotherapy, Endocrine therapy, Immunotherapy and Others. By Route of Administration– Parenteral, Oral and Others. By Application– Hospitals, Biotechnology & Pharmaceutical company, Specialty Clinics, Research & Academic Institution and Others. By Distribution channel- Hospital pharmacy, Retail pharmacy and Online pharmacy. |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the HER2-Positive Breast Cancer market report based on treatment type, route of administration, application, distribution channel and region.
HER2-Positive Breast Cancer Market, By Region:
- North America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- U.S.
- Canada
- Middle East & Africa
Global HER2 Positive Breast Cancer Market Key Players
The key players operating in the HER2-Positive Breast Cancer market includes Pfizer Inc., Eli Lilly and Company, Immunomedics, AstraZeneca, F. Hoffmann-La Roche Ltd, Radius pharmaceuticals, Merck & Co., Inc, Bayer AG, GlaxoSmithKline plc, Syndax pharmaceuticals, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceuticals Industries Ltd, Baxter, Mylan N.V., and Fresenius Kabi AG among others.
Global HER2 Positive Breast Cancer Market Company Profile
- Pfizer, Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Immunomedics
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- Radius pharmaceuticals
- Merck & Co. Inc
- Bayer AG
- GlaxoSmithKline plc
- Syndax pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceuticals Industries Ltd
- Baxter
- Mylan N.V.
- Fresenius Kabi AG
- Others.
“*” marked represents similar segmentation in other categories in the respective section.
Global HER2 Positive Breast Cancer Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for HER2-Positive Breast Cancer Strategies
- Key Questions this Study will Answer
- Market Snippet, By Treatment type
- Market Snippet, By Route of administration
- Market Snippet, By Application
- Market Snippet, By Distribution channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Treatment type, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Targeted therapy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Chemotherapy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Endocrine therapy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Immunotherapy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By Route of administration, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Parenteral
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Oral
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By Application, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Biotechnology & Pharmaceutical company
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Specialty Clinics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Research and Academic Institution
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By Distribution channel, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospital pharmacy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Retail pharmacy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Online pharmacy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Overview
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Asia Pacific
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Immunomedics
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- Radius pharmaceuticals
- Merck & Co. Inc
- Bayer AG
- GlaxoSmithKline plc
- Syndax pharmaceuticals
The Last Word
- Future Impact
- About Us
- Contact
Global HER2 Positive Breast Cancer Market Highlights
FAQs
HER2-Positive Breast Cancer market is segmented based on treatment type, route of administration, application, distribution channel and region.
The expansion of this industry is due to emerging markets and significant investment in research & development.
North America will hold the largest market share for HER2-positive breast cancer therapy and it is because of the growth in incidences of HER2-positive breast cancer and favourable government regulations as well as advanced healthcare facilities.
The key players operating in the HER2-Positive Breast Cancer market includes Pfizer Inc., Eli Lilly and Company, Immunomedics, AstraZeneca, F. Hoffmann-La Roche Ltd, Radius pharmaceuticals, Merck & Co., Inc, Bayer AG, GlaxoSmithKline plc, Syndax pharmaceuticals, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceuticals Industries Ltd, Baxter, Mylan N.V., and Fresenius Kabi AG among others.